Latest news with #Selinexor
Yahoo
5 days ago
- Health
- Yahoo
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms
Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, along with advancements in targeted therapies and early diagnostic tools, are key factors driving market growth. New York, USA, July 15, 2025 (GLOBE NEWSWIRE) -- Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, along with advancements in targeted therapies and early diagnostic tools, are key factors driving market growth. DelveInsight's 'Endometrial Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometrial cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the endometrial cancer pipeline domain. Key Takeaways from the Endometrial Cancer Pipeline Report DelveInsight's endometrial cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline endometrial cancer drugs. Key endometrial cancer companies such as Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imvax, and others are evaluating new endometrial cancer drugs to improve the treatment landscape. Promising pipeline endometrial cancer therapies, such as Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others, are in different phases of endometrial cancer clinical trials. In June 2025, Daiichi Sankyo announced the first patient had been dosed in the DESTINY-Endometrial01 clinical trial evaluating Enhertu (trastuzumab deruxtecan) in combination with rilvegostomig or Merck's Keytruda (pembrolizumab) as a first-line treatment for patients with HER2-expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer. In May 2025, Kaida BioPharma announced it had entered into a manufacturing agreement with Northway Biotech, Inc., an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), for the manufacturing of lead product candidate, a novel biologic prolactin receptor antagonist, is being initially developed for the treatment of platinum-resistant ovarian cancer (PROC) with expansion opportunities into endometrial, uterine, and breast cancers. In May 2025, PRISM BioLab, Co. Ltd. announced that the analysis of a combination study of E7386 created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797), expansion cohort of advanced endometrial cancer patients who progressed following platinum-based chemotherapy and anti-PD (L)1 immunotherapy have been implemented by Eisai, and the enrollment of 30 patients was completed. In March 2025, Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) announced that the first patient has been dosed in its Phase II combination trial of PIKTOR, which is FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel. The trial is the most advanced of its kind to investigate a novel approach of dual PI3Kɑ-mTORC1/2 inhibition targeting cancer metabolism in patients with endometrial cancer. In February 2025, Acrivon Therapeutics announced that the FDA had granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer. In December 2024, Repare Therapeutics Inc. reported positive data from its MYTHIC Phase I gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase II dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. In December 2024, IDEAYA Biosciences, Inc. announced that it has dosed the first patient in the IDEAYA-sponsored Phase I trial evaluating the combination of IDE161, the company's investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in endometrial cancer patients with high microsatellite instability (MSI-high) and microsatellite stable(MSS). Request a sample and discover the recent advances in endometrial cancer drugs @ Endometrial Cancer Pipeline Report The endometrial cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometrial cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the endometrial cancer clinical trial landscape. Endometrial Cancer Overview Endometrial cancer, which arises from the uterus's inner lining (the endometrium), is the most common gynecologic cancer in developed countries, with its occurrence steadily increasing. This rise is linked to factors like aging populations and growing obesity rates. Most diagnoses occur in postmenopausal women, with abnormal uterine bleeding being the most frequent symptom. Because this symptom often prompts early medical evaluation, many cases are detected at an initial stage, improving treatment success. Several risk factors play a role in the development of endometrial cancer. Obesity, metabolic syndrome, and diabetes are key contributors, with obesity responsible for about 40% of cases. Reproductive history, such as early onset of menstruation, delayed menopause, never having given birth, and infertility, also raises risk. Genetic factors, especially Lynch syndrome, increase susceptibility. In contrast, combined oral contraceptives have been linked to a decreased risk. Diagnosis usually involves an endometrial biopsy, often following a transvaginal ultrasound to measure endometrial thickness. However, research suggests transvaginal ultrasound can produce false-negative results, particularly in Black women, indicating that biopsy remains the definitive diagnostic method. Surgical staging, based on the International Federation of Gynecology and Obstetrics (FIGO) criteria, is essential for assessing disease extent and planning treatment. Treatment varies by stage. Early-stage disease is generally treated with a total hysterectomy and removal of both ovaries and fallopian tubes. Additional therapies such as radiation or chemotherapy may be recommended depending on risk factors. For advanced or recurrent disease, newer treatments like immunotherapy show promise. In particular, the combination of dostarlimab (JEMPERLI) with chemotherapy has improved survival in advanced or recurrent cases. Research continues to evolve to optimize these treatment approaches and improve patient out more about endometrial cancer drugs @ Endometrial Cancer Treatment A snapshot of the Pipeline Endometrial Cancer Drugs mentioned in the report: Drugs Company Phase MoA RoA Selinexor Karyopharm Therapeutics III Exportin 1 protein inhibitors Oral EG-007 Evergreen Therapeutics III Epidermal growth factor receptor antagonists Injectable Abemaciclib Eli Lilly and Company II Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors Oral Envafolimab Alphamab Oncology/Ascletis/3D Medicine II Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants Subcutaneous Sirexatamab (DKN-01) Leap Therapeutics II DKK1 protein inhibitors Intravenous NP137 NETRIS Pharma II Antibody-dependent cell cytotoxicity; T lymphocyte stimulants Intravenous COM 701 Compugen I/II Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants Intravenous XMT-1660 Mersana Therapeutics I Tubulin inhibitors Intravenous Learn more about the emerging endometrial cancer therapies @ Endometrial Cancer Clinical Trials Endometrial Cancer Therapeutics Assessment The endometrial cancer pipeline report proffers an integral view of the emerging endometrial cancer therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Endometrial Cancer Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Exportin 1 protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, DKK1 protein inhibitors, Tubulin inhibitors, Epidermal growth factor receptor antagonists Key Endometrial Cancer Companies: Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imva,x and others. Key Endometrial Cancer Pipeline Therapies: Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others. Dive deep into rich insights for new endometrial cancer treatments, visit @ Endometrial Cancer Drugs Table of Contents 1. Endometrial Cancer Pipeline Report Introduction 2. Endometrial Cancer Pipeline Report Executive Summary 3. Endometrial Cancer Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Endometrial Cancer Clinical Trial Therapeutics 6. Endometrial Cancer Pipeline: Late-Stage Products (Pre-registration) 7. Endometrial Cancer Pipeline: Late-Stage Products (Phase III) 8. Endometrial Cancer Pipeline: Mid-Stage Products (Phase II) 9. Endometrial Cancer Pipeline: Early-Stage Products (Phase I) 10. Endometrial Cancer Pipeline Therapeutics Assessment 11. Inactive Products in the Endometrial Cancer Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Endometrial Cancer Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the endometrial cancer pipeline therapeutics, reach out @ Endometrial Cancer Therapeutics Related Reports Endometrial Cancer Epidemiology Forecast Endometrial Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted endometrial cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Endometrial Cancer Market Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including GlaxoSmithKline, Merck & Co, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Incyte Corporation, among others. Advanced Endometrial Cancer Pipeline Advanced Endometrial Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced endometrial cancer companies, including Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech, Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics, Inc., Celon Pharma SA, Dragonfly Therapeutics, among others. Endometriosis Pipeline Endometriosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others. Endometriosis Pain Market Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. Endometriosis Pain Pipeline Endometriosis Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn CONTACT: Contact Us Shruti Thakur info@ +14699457679 in to access your portfolio
Business Upturn
5 days ago
- Business
- Business Upturn
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms
By GlobeNewswire Published on July 15, 2025, 22:00 IST New York, USA, July 15, 2025 (GLOBE NEWSWIRE) — Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, along with advancements in targeted therapies and early diagnostic tools, are key factors driving market growth. DelveInsight's 'Endometrial Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometrial cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the endometrial cancer pipeline domain. Key Takeaways from the Endometrial Cancer Pipeline Report DelveInsight's endometrial cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline endometrial cancer drugs. active players working to develop pipeline endometrial cancer drugs. Key endometrial cancer companies such as Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics , Leap Therapeutics , Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imvax, and others are evaluating new endometrial cancer drugs to improve the treatment landscape. and others are evaluating new endometrial cancer drugs to improve the treatment landscape. Promising pipeline endometrial cancer therapies, such as Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others, are in different phases of endometrial cancer clinical trials. and others, are in different phases of endometrial cancer clinical trials. In June 2025, Daiichi Sankyo announced the first patient had been dosed in the DESTINY-Endometrial01 clinical trial evaluating Enhertu (trastuzumab deruxtecan) in combination with rilvegostomig or Merck's Keytruda (pembrolizumab) as a first-line treatment for patients with HER2-expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer. In May 2025, Kaida BioPharma announced it had entered into a manufacturing agreement with Northway Biotech, Inc., an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), for the manufacturing of lead product candidate, a novel biologic prolactin receptor antagonist, is being initially developed for the treatment of platinum-resistant ovarian cancer (PROC) with expansion opportunities into endometrial, uterine, and breast cancers. In May 2025, PRISM BioLab, Co. Ltd. announced that the analysis of a combination study of E7386 created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797), expansion cohort of advanced endometrial cancer patients who progressed following platinum-based chemotherapy and anti-PD (L)1 immunotherapy have been implemented by Eisai, and the enrollment of 30 patients was completed. In March 2025, Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) announced that the first patient has been dosed in its Phase II combination trial of PIKTOR, which is FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel. The trial is the most advanced of its kind to investigate a novel approach of dual PI3Kɑ-mTORC1/2 inhibition targeting cancer metabolism in patients with endometrial cancer. In February 2025, Acrivon Therapeutics announced that the FDA had granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer. In December 2024, Repare Therapeutics Inc. reported positive data from its MYTHIC Phase I gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase II dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. In December 2024, IDEAYA Biosciences, Inc. announced that it has dosed the first patient in the IDEAYA-sponsored Phase I trial evaluating the combination of IDE161, the company's investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in endometrial cancer patients with high microsatellite instability (MSI-high) and microsatellite stable(MSS). Request a sample and discover the recent advances in endometrial cancer drugs @ Endometrial Cancer Pipeline Report The endometrial cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometrial cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the endometrial cancer clinical trial landscape. Endometrial Cancer Overview Endometrial cancer, which arises from the uterus's inner lining (the endometrium), is the most common gynecologic cancer in developed countries, with its occurrence steadily increasing. This rise is linked to factors like aging populations and growing obesity rates. Most diagnoses occur in postmenopausal women, with abnormal uterine bleeding being the most frequent symptom. Because this symptom often prompts early medical evaluation, many cases are detected at an initial stage, improving treatment success. Several risk factors play a role in the development of endometrial cancer. Obesity, metabolic syndrome, and diabetes are key contributors, with obesity responsible for about 40% of cases. Reproductive history, such as early onset of menstruation, delayed menopause, never having given birth, and infertility, also raises risk. Genetic factors, especially Lynch syndrome, increase susceptibility. In contrast, combined oral contraceptives have been linked to a decreased risk. Diagnosis usually involves an endometrial biopsy, often following a transvaginal ultrasound to measure endometrial thickness. However, research suggests transvaginal ultrasound can produce false-negative results, particularly in Black women, indicating that biopsy remains the definitive diagnostic method. Surgical staging, based on the International Federation of Gynecology and Obstetrics (FIGO) criteria, is essential for assessing disease extent and planning treatment. Treatment varies by stage. Early-stage disease is generally treated with a total hysterectomy and removal of both ovaries and fallopian tubes. Additional therapies such as radiation or chemotherapy may be recommended depending on risk factors. For advanced or recurrent disease, newer treatments like immunotherapy show promise. In particular, the combination of dostarlimab (JEMPERLI) with chemotherapy has improved survival in advanced or recurrent cases. Research continues to evolve to optimize these treatment approaches and improve patient outcomes. Find out more about endometrial cancer drugs @ Endometrial Cancer Treatment A snapshot of the Pipeline Endometrial Cancer Drugs mentioned in the report: Drugs Company Phase MoA RoA Selinexor Karyopharm Therapeutics III Exportin 1 protein inhibitors Oral EG-007 Evergreen Therapeutics III Epidermal growth factor receptor antagonists Injectable Abemaciclib Eli Lilly and Company II Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors Oral Envafolimab Alphamab Oncology/Ascletis/3D Medicine II Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants Subcutaneous Sirexatamab (DKN-01) Leap Therapeutics II DKK1 protein inhibitors Intravenous NP137 NETRIS Pharma II Antibody-dependent cell cytotoxicity; T lymphocyte stimulants Intravenous COM 701 Compugen I/II Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants Intravenous XMT-1660 Mersana Therapeutics I Tubulin inhibitors Intravenous Learn more about the emerging endometrial cancer therapies @ Endometrial Cancer Clinical Trials Endometrial Cancer Therapeutics Assessment The endometrial cancer pipeline report proffers an integral view of the emerging endometrial cancer therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Endometrial Cancer Pipeline Report Coverage : Global : Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Exportin 1 protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, DKK1 protein inhibitors, Tubulin inhibitors, Epidermal growth factor receptor antagonists : Exportin 1 protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, DKK1 protein inhibitors, Tubulin inhibitors, Epidermal growth factor receptor antagonists Key Endometrial Cancer Companies : Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imva,x and others. : Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imva,x and others. Key Endometrial Cancer Pipeline Therapies: Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others. Dive deep into rich insights for new endometrial cancer treatments, visit @ Endometrial Cancer Drugs Table of Contents 1. Endometrial Cancer Pipeline Report Introduction 2. Endometrial Cancer Pipeline Report Executive Summary 3. Endometrial Cancer Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Endometrial Cancer Clinical Trial Therapeutics 6. Endometrial Cancer Pipeline: Late-Stage Products (Pre-registration) 7. Endometrial Cancer Pipeline: Late-Stage Products (Phase III) 8. Endometrial Cancer Pipeline: Mid-Stage Products (Phase II) 9. Endometrial Cancer Pipeline: Early-Stage Products (Phase I) 10. Endometrial Cancer Pipeline Therapeutics Assessment 11. Inactive Products in the Endometrial Cancer Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Endometrial Cancer Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the endometrial cancer pipeline therapeutics, reach out @ Endometrial Cancer Therapeutics Related Reports Endometrial Cancer Epidemiology Forecast Endometrial Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted endometrial cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Endometrial Cancer Market Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including GlaxoSmithKline, Merck & Co, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Incyte Corporation, among others. Advanced Endometrial Cancer Pipeline Advanced Endometrial Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced endometrial cancer companies, including Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech, Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics, Inc., Celon Pharma SA, Dragonfly Therapeutics, among others. Endometriosis Pipeline Endometriosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others. Endometriosis Pain Market Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. Endometriosis Pain Pipeline Endometriosis Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Globe and Mail
17-02-2025
- Health
- Globe and Mail
Thrombocytopenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approval, Incidence, Therapies, and Companies by DelveInsight
Thrombocytopenia Companies such as Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo and others. (Albany, USA) DelveInsight's ' Thrombocytopenia Market Insights, Epidemiology and Market Forecast – 2034 ' report delivers an in-depth understanding of thrombocytopenia, historical and forecasted epidemiology as well as the thrombocytopenia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. The Thrombocytopenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Thrombocytopenia market size from 2020 to 2034, segmented by seven major markets. The Thrombocytopenia Market Report also covers current Thrombocytopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Thrombocytopenia market. Explore the intricate details of the Thrombocytopenia Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Thrombocytopenia Market Forecast. Click here to stay ahead in healthcare innovation @ Thrombocytopenia Market Size Key Takeaways from the Thrombocytopenia Market Report The United States accounts for the largest market size (around 60%) of thrombocytopenia, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. Among all cases of thrombocytopenia in the United States, the largest group consists of those with heparin-induced thrombocytopenia followed by chronic liver disease. DelveInsight's consultant estimates that the United States accounts for approximately 20% of total cases of Thrombocytopenia in Chronic Liver Disease, in the 7MM. The United States had the highest cases of thrombotic thrombocytopenia compared to EU4 and the UK and Japan, as assessed in 2023. The leading Thrombocytopenia Companies such as Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo and others. Promising Thrombocytopenia Therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, Selinexor 60 mg, Nipocalimab, QL0911, and others. June 2024:- Qidong Gaitianli Medicines Co., Ltd- A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency). June 2024:- Karyopharm Therapeutics Inc.- A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia. The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study. June 2024:- Janssen Research & Development LLC- Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies. The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). June 2024:- Amgen- A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer. June 2024:- Qilu Pharmaceuticals Ltd- Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia. To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment. Navigate the complexities of the Thrombocytopenia Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Thrombocytopenia Market Forecast. Click here to get more insights @ Thrombocytopenia Treatment Market Thrombocytopenia Epidemiology Segmentation in the 7MM Total Thrombocytopenia Cases Total Cases of Immune Thrombocytopenia Total Cases of Thrombocytopenia in Chronic Liver Disease Total Cases of Chemotherapy-induced Thrombocytopenia Total Number of Cases of Heparin-induced Thrombocytopenia Total Thrombocytopenia Cases Delve deep into the Thrombocytopenia Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Thrombocytopenia Market Forecast. Click here to shape the future @ Thrombocytopenia Prevalence Thrombocytopenia Marketed Drugs • ADZYNMA: Takeda ADZYNMA (ADAMTS13, recombinant-krhn) is a human recombinant (a disintegrin and metalloproteinase with thrombospondin motifs 13) ADAMTS13 (rADAMTS13) indicated for prophylactic or on-demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA was previously granted Orphan Drug Designation (ODD) by the US FDA for the treatment and prevention of TTP, including its acquired idiopathic and secondary forms, as well as Fast Track and Rare Pediatric Disease Designation. The US FDA also granted Takeda a Rare Pediatric Disease Voucher for the approval of ADZYNMA. ADZYNMA has also been granted ODD by the European Medicines Agency (EMA) and Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of TTP. • TAVALISSE (fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical Fostamatinib disodium (also known as TAVALISSE; R-985788) is an orally-bioavailable investigational agent being developed by Rigel pharmaceuticals and approved for the treatment of patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. The therapeutic candidate inhibits FcR-triggered, Syk-dependent cytoskeletal rearrangement during phagocytosis. Thrombocytopenia Emerging Drugs • Rilzabrutinib (PRN-1008): Sanofi/Principia Biopharma Rilzabrutinib (PRN-1008) is an orally administered reversible covalent inhibitor of Bruton tyrosine kinase (BTK). BTK is an essential signaling element downstream of the B-cell receptor (BCR), Fc-gamma receptor, and Fc-epsilon receptor pathways. Rilzabrutinib is currently being evaluated in the Phase III stage of development to treat ITP in adults and adolescents with persistent or chronic ITP. Recently, the LUNA 3 Phase III study showed that rilzabrutinib at a dose of 400 mg twice daily orally successfully met the primary endpoint of achieving a durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP). The safety profile observed for rilzabrutinib in this study was consistent with previous findings from other studies. Thrombocytopenia Market Insights Thrombocytopenia is a condition in which the blood has a lower than the normal platelet count. When a patient's blood has too few platelets, mild to serious bleeding can occur. Bleeding can be internal or underneath the skin, or external. The approved therapies for treating thrombocytopenia in the US include MULPLETA, DOPTELET,TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. These therapies are approved for various patient groups; for example, MULPLETA and DOPTELET are approved for thrombocytopenia in chronic liver disease, PROMACTA is approved for chronic immune (idiopathic) thrombocytopenic purpura (ITP). Thrombocytopenia Treatment Landscape Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding. The approved therapies for treating thrombocytopenia in the US include MULPLETA, DOPTELET, TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. Danaparoid, argatroban, and lepirudin were approved in the US to treat thrombosis in patients with heparin-induced thrombocytopenia. Current treatment options for severe thrombocytopenia in chronic liver disease include platelet transfusion, splenic artery embolization, splenectomy, and placement of a transjugular intrahepatic portosystemic stent shunt (TIPSS). Gain a strategic edge in the Thrombocytopenia Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Thrombocytopenia Market Forecast. Click here to lead in advancements @ Thrombocytopenia Clinical Trials Assessment Scope of the Thrombocytopenia Market Report Coverage- 7MM Thrombocytopenia Companies- Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo and others. Thrombocytopenia Therapies- VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, Selinexor 60 mg, Nipocalimab, QL0911, and others. Thrombocytopenia Market Dynamics: Thrombocytopenia Market drivers and Thrombocytopenia Market Barriers Thrombocytopenia Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Thrombocytopenia Unmet Needs, KOL's views, Analyst's views, Thrombocytopenia Market Access and Reimbursement Table of Content 1. Key Insights 2. Report Introduction 3. Thrombocytopenia Market Overview at a Glance 4. Executive Summary of Thrombocytopenia 5. Key events 6. Thrombocytopenia Market Disease Background and Overview 7. Thrombocytopenia Methodology 8. Thrombocytopenia Epidemiology and Patient Population 9. Patient Journey 10. Thrombocytopenia Marketed Products 11. Thrombocytopenia Emerging Therapies 12. Thrombocytopenia Seven Major Market Analysis 13. Market Access and Reimbursement 14. KOL Views 15. Thrombocytopenia Unmet Needs 16. SWOT Analysis 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
